Mpox is “not the new Covid,” according to a leading expert from the World Health Organization (WHO), who emphasized that authorities are equipped to manage its spread effectively. Dr. Hans Kluge, the European regional director at WHO, addressed concerns about a new variant of the virus amidst a global alert, stating that collective action is essential to combat mpox.
Dr. Kluge stressed that prompt action, including equitable vaccine distribution to high-risk areas, could prevent another cycle of fear and neglect. Recent developments include a confirmed case of the new variant, Clade Ib, in Sweden, which is associated with a rising outbreak in Africa.
In the Democratic Republic of Congo, Clade Ib has resulted in at least 450 fatalities over the past months. Experts are still investigating this new variant, indicating it may be more transmissible and cause more severe disease. While there have been no reported cases of Clade Ib in the UK, experts warn that it could spread without decisive international intervention.
Clade II, a different variant, was responsible for the 2022 outbreak that initially impacted Europe and remains prevalent in many regions worldwide. Despite the ongoing risks, Dr. Kluge reassured the public that effective strategies exist to control mpox, emphasizing the importance of inclusive public health initiatives and fair access to vaccines.
Mpox, characterized by fever and rash, is transmitted through skin-to-skin contact with lesions, including during intimate encounters. Dr. Kluge maintained that the risk level for the general population remains low, rejecting the notion of lockdowns or crisis measures similar to those used during the Covid-19 pandemic.
Reflecting on the earlier response to mpox in 2022, he noted that direct engagement with the most affected communities played a critical role in controlling the virus’s spread. However, with approximately 100 new Clade II cases reported in Europe monthly, he urged that global cooperation is crucial to address and eliminate mpox.
Travelers visiting affected areas in Africa are advised to consider vaccination. WHO representatives have clarified that while mass vaccination is not recommended, targeted vaccine use in outbreak scenarios for high-risk groups is essential.
